Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Novel target to prevent heart attacks and strokes discovered at Lexicon

Nov. 19, 2002

New alphavbeta6 integrin antagonists in early development at Merck KGaA

Nov. 18, 2002

Oral factor Xa inhibitor enters phase I study for the treatment of thrombotic diseases

Nov. 15, 2002

Drug safety announcement regarding Refludan

Nov. 14, 2002

Exanta proves superior to routinely used enoxaparin for reducing risk of VTE in major surgery

Nov. 14, 2002

Merck scientists present novel inhibitors of factor Xa and/or factor VIIa

Nov. 14, 2002

Initiation of phase III trial of eptifibatide in heart attack

Nov. 13, 2002

APT-3111 awarded E.U. orphan drug status for paroxysmal nocturnal hemoglobinuria

Nov. 12, 2002

Phase II trials initiated with novel anticoagulant rNAPc2

Nov. 11, 2002

Novel factor Xa and/or factor VIIa inhibitors in early development at Merck KGaA

Nov. 6, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.